Tamara Alpermann

7.6k citations
88 papers · 2.8k · h-index 29

Impact in

  • Hematology top 0.2%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
  • Genetics top 0.5%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment
    • Chronic Lymphocytic Leukemia Research

Papers in

  • Hematology 77
    • Acute Myeloid Leukemia Research 74
    • Chronic Myeloid Leukemia Treatments 22
  • Genetics 45
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 28
    • Chronic Lymphocytic Leukemia Research 19
Co-authors
Wolfgang Kern (82 shared papers)Claudia Haferlach (79 shared papers)Susanne Schnittger (79 shared papers)Torsten Haferlach (79 shared papers)Ulrike Bacher (33 shared papers)Frank Dicker (26 shared papers)Alexander Kohlmann (32 shared papers)Vera Grossmann (15 shared papers)
Journals
Blood (37 papers)Leukemia (12 papers)British Journal of Haematology (8 papers)Haematologica (7 papers)Genes Chromosomes and Cancer (6 papers)
Partner nations
GermanyUnited StatesSingapore

In The Last Decade

Tamara Alpermann

85 papers receiving 2.8k citations

Peers

Tamara Alpermann
Comparison fields: 5 of 72
  • Hematology 2.2k
  • Genetics 1.3k
  • Cancer Research 421
  • Pathology and Forensic Medicine 329
  • Molecular Biology 1.2k
Replace Christine L. O’Keefe with:
Christine L. O’Keefe United States
Olivier Kosmider France
Véronique Gelsi‐Boyer France
Vera Grossmann Germany
Zuzana Zemanová Czechia
Christine Terré France
J W Vardiman United States
Olivier Nibourel France
Hadrian Szpurka United States
Dimitri Breems Netherlands
Tamara Alpermann relative to Christine L. O’Keefe United States Christine L. O’Keefe's profile →
Citations per field
00.5×2×2.6×
Christine L. O’Keefe · 1×
Citations per year

Countries citing papers authored by Tamara Alpermann

Since Specialization
Citations

This map shows the geographic impact of Tamara Alpermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamara Alpermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamara Alpermann more than expected).

Fields of papers citing papers by Tamara Alpermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamara Alpermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamara Alpermann. The network helps show where Tamara Alpermann may publish in the future.

Co-authors

The 25 scholars most cited alongside Tamara Alpermann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tamara Alpermann Line = papers co-authored together Tamara Alpermann links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 88 papers — load more, or switch the sort, to bring in the rest.

#Work
1
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)
Blood ·Manja Meggendorfer, Andreas Roller, Torsten Haferlach, Christiane Eder, Frank Dicker, Vera Grossmann, Alexander Kohlmann, Tamara Alpermann, Kenichi Yoshida, Seishi Ogawa, H. Phillip Koeffler, Wolfgang Kern, Claudia Haferlach, Susanne Schnittger
2012219
2
Landscape of TET2 mutations in acute myeloid leukemia
Leukemia ·Sandra Weißmann, Tamara Alpermann, Vera Grossmann, Andreas Kowarsch, Niroshan Nadarajah, Christiane Eder, Frank Dicker, Annette Fasan, Claudia Haferlach, Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, Alexander Kohlmann
2011183
3
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis
Blood ·Susanne Schnittger, Frank Dicker, Wolfgang Kern, Nicole Wendland, Jana Sundermann, Tamara Alpermann, Claudia Haferlach, Torsten Haferlach
2010181
4
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
Blood ·Susanne Schnittger, Claudia Haferlach, Madlen Ulke, Tamara Alpermann, Wolfgang Kern, Torsten Haferlach
2010160
5
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome
Leukemia ·Susanne Schnittger, Christiane Eder, Sabine Jeromin, Tamara Alpermann, Annette Fasan, Vera Grossmann, Alexander Kohlmann, Thomas Illig, N. Klopp, H-E Wichmann, K.-A. Kreuzer, Christoph Schmid, Peter Staib, Rudolf Peceny, Norbert Schmitz, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
2012153
6
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
Leukemia ·Sabine Jeromin, Sandra Weißmann, Claudia Haferlach, Frank Dicker, Katharina Bayer, Vera Grossmann, Tamara Alpermann, Andreas Roller, Alexander Kohlmann, Torsten Haferlach, Wolfgang Kern, Susanne Schnittger
2013144
7
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations
Leukemia ·Manja Meggendorfer, Ulrike Bacher, Tamara Alpermann, Claudia Haferlach, Wolfgang Kern, Carlo Gambacorti‐Passerini, Torsten Haferlach, Susanne Schnittger
2013125
8
The role of different genetic subtypes of CEBPA mutated AML
Leukemia ·Annette Fasan, Claudia Haferlach, Tamara Alpermann, Sabine Jeromin, Vera Grossmann, Christiane Eder, Sandra Weißmann, Frank Dicker, Alexander Kohlmann, Sonja Schindela, Wolfgang Kern, Torsten Haferlach, Susanne Schnittger
2013116
9
High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome
Leukemia ·M-T Krauth, Christiane Eder, Tamara Alpermann, Ulrike Bacher, Niroshan Nadarajah, Wolfgang Kern, Claudia Haferlach, T. Haferlach, Susanne Schnittger
201493
10
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease
Leukemia ·Alexander Kohlmann, Niroshan Nadarajah, Tamara Alpermann, Vera Grossmann, Sonja Schindela, Frank Dicker, Andreas Roller, Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach
201380
11
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia
Leukemia ·Susanne Schnittger, Ulrike Bacher, Wolfgang Kern, Tamara Alpermann, Claudia Haferlach, Torsten Haferlach
201179
12
Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups
Cancer ·Ursula Creutzig, Martin Zimmermann, Dirk Reinhardt, Mareike Rasche, Christine von Neuhoff, Tamara Alpermann, Michael Dworzak, Karolína Perglerová, Zuzana Zemanová, Joëlle Tchinda, Jutta Bradtke, Christian Thiede, Claudia Haferlach
201676
13
BCOR regulates myeloid cell proliferation and differentiation
Leukemia ·Qi Cao, Micah D. Gearhart, Sigal Gery, Seyedmehdi Shojaee, Henry Yang, Haibo Sun, De-Chen J Lin, J-w Bai, Monica Mead, Zhiqiang Zhao, Q. Chen, W-w Chien, Serhan Alkan, Tamara Alpermann, Torsten Haferlach, Markus Müschen, Vivian J. Bardwell, H. Phillip Koeffler
201666
14
Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis
Leukemia ·Julien Broséus, Tamara Alpermann, Michael Wulfert, Lourdes Florensa, Sabine Jeromin, Éric Lippert, Marı́a Rozman, François Lifermann, Vera Großmann, Torsten Haferlach, Ulrich Germing, Elisa Luño, François Girodon, Susanne Schnittger, (unknown)
201366
15
Diversity of the juxtamembrane and TKD1 mutations (Exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data
Genes Chromosomes and Cancer ·Susanne Schnittger, Ulrike Bacher, Claudia Haferlach, Tamara Alpermann, Wolfgang Kern, Torsten Haferlach
201264
16
WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups
Leukemia ·M-T Krauth, Tamara Alpermann, Ulrike Bacher, Christiane Eder, Frank Dicker, Madlen Ulke, Sabrina Kuznia, Niroshan Nadarajah, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach, Susanne Schnittger
201457
17
Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia
Haematologica ·Vera Grossmann, Wolfgang Kern, Stefan Harbich, Tamara Alpermann, S. Jeromin, Susanne Schnittger, Claudia Haferlach, Torsten Haferlach, Alexander Kohlmann
201155
18
Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype
Blood ·Claudia Haferlach, Tamara Alpermann, Susanne Schnittger, Wolfgang Kern, Jörg Chromik, Christoph Schmid, H.-J. Pielken, Karl‐Anton Kreuzer, Heinz‐Gert Höffkes, Torsten Haferlach
201151
19
Monoclonal B‐cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early‐stage CLL
British Journal of Haematology ·Wolfgang Kern, Ulrike Bacher, Claudia Haferlach, Frank Dicker, Tamara Alpermann, Susanne Schnittger, Torsten Haferlach
201245
20
Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA
Haematologica ·S. Schnittger, Ulrike Bacher, Claudia Haferlach, Wolfgang Kern, Tamara Alpermann, T. Haferlach
201142

About Tamara Alpermann

Tamara Alpermann is a scholar working on Hematology, Genetics, Molecular Biology, Public Health, Environmental and Occupational Health and Pathology and Forensic Medicine, having authored 88 papers that have together received 2.8k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (74 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (28 papers), Chronic Myeloid Leukemia Treatments (22 papers), Chronic Lymphocytic Leukemia Research (19 papers), Acute Lymphoblastic Leukemia research (14 papers), Lymphoma Diagnosis and Treatment (12 papers), Cancer Genomics and Diagnostics (11 papers) and Protein Degradation and Inhibitors (7 papers). The work is most often cited by research in Hematology (2.2k citations), Genetics (1.3k citations), Cancer Research (421 citations), Pathology and Forensic Medicine (329 citations) and Molecular Biology (1.2k citations). Tamara Alpermann has collaborated with scholars based in Germany, United States and Singapore. Frequent co-authors include Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach, Ulrike Bacher, Frank Dicker, Alexander Kohlmann, Vera Grossmann, Christiane Eder and Niroshan Nadarajah. Their work appears in journals such as Blood, Leukemia, British Journal of Haematology, Haematologica and Genes Chromosomes and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christine L. O’KeefeBreakdown of academic impact, for papers by Olivier KosmiderBreakdown of academic impact, for papers by Véronique Gelsi‐BoyerBreakdown of academic impact, for papers by Vera GrossmannBreakdown of academic impact, for papers by Zuzana ZemanováBreakdown of academic impact, for papers by Christine TerréBreakdown of academic impact, for papers by J W VardimanBreakdown of academic impact, for papers by Olivier NibourelBreakdown of academic impact, for papers by Hadrian SzpurkaBreakdown of academic impact, for papers by Dimitri Breems